Modality
Peptide
MOA
PI3Ki
Target
BCMA
Pathway
Angiogenesis
SMASCD
Development Pipeline
Preclinical
Apr 2021
→ Dec 2030
PreclinicalCurrent
NCT04870447
1,204 pts·SMA
2025-07→2030-12·Active
NCT03620134
2,394 pts·SMA
2021-04→2028-10·Terminated
3,598 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2028-10-212.6y awayInterim· SMA
2030-12-254.7y awayInterim· SMA
Trial Timeline
Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
Preclinical
Termina…
Preclinical
Active
Catalysts
Interim
2028-10-21 · 2.6y away
SMA
Interim
2030-12-25 · 4.7y away
SMA
ActiveTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04870447 | Preclinical | SMA | Active | 1204 | HAM-D |
| NCT03620134 | Preclinical | SMA | Terminated | 2394 | VA |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-1956 | Eli Lilly | Phase 1/2 | BCMA | |
| Tiramavacamten | Roche | Preclinical | SGLT2 | |
| NVS-5126 | Novartis | Phase 3 | SHP2 | |
| ABB-8696 | AbbVie | Phase 3 | BCMA | |
| Voxacilimab | AstraZeneca | Phase 1/2 | GLP-1R | |
| AZN-4015 | AstraZeneca | Preclinical | BCMA | |
| Capifutibatinib | Sanofi | Approved | PRMT5 | |
| Rimatenlimab | Novo Nordisk | Phase 2/3 | SGLT2 | |
| REG-3155 | Regeneron | Phase 1/2 | MDM2 | |
| REG-2328 | Regeneron | Phase 1 | BCMA |